澳大利亞生物技術(shù)投資峰會(huì)邀請(qǐng)函

瀏覽次數(shù)：7087　發(fā)布日期：2013-9-12　來源：本站　本站原創(chuàng)，轉(zhuǎn)載請(qǐng)注明出處

澳大利亞生物技術(shù)投資峰會(huì)

澳大利亞生物技術(shù)投資峰會(huì)

2013年10月28-29日 | 澳大利亞 . 墨爾本會(huì)展中心

澳大利亞首屈一指的生物技術(shù)投資盛會(huì)

由澳大利亞生物技術(shù)協(xié)會(huì)（Ausbiotech Association）和精肯會(huì)展聯(lián)合舉辦的首屆『澳大利亞生物技術(shù)投資峰會(huì)』將于10月28日至29日假墨爾本會(huì)展中心舉行。

自2013年開始，澳大利亞生物技術(shù)協(xié)會(huì)和精肯會(huì)展聯(lián)合創(chuàng)辦了生物技術(shù)投資峰會(huì)資系列，包括剛于6月在香港圓滿結(jié)束的首屆『亞洲生物技術(shù)投資峰會(huì)』，會(huì)議共得230多名生物技術(shù)權(quán)威領(lǐng)導(dǎo)和亞洲生物技術(shù)投資者參加，17家生物技術(shù)公司作出自我介紹，引來從多投資者興趣。另外，50多名嘉賓發(fā)表演說，探討從多富爭(zhēng)論性的議題。

結(jié)合高價(jià)值的內(nèi)容，具體的投資機(jī)會(huì)

除了30多場(chǎng)生物技術(shù)公司介紹，澳大利亞生物技術(shù)投資峰會(huì)還結(jié)合專家主題演講，投資者和分析師的專題和重點(diǎn)討論，為您提供機(jī)具價(jià)值的市場(chǎng)情報(bào)和作為生物技術(shù)投資指南。

二十九家生物技術(shù)公司已經(jīng)落實(shí)參加公司推介

其他與會(huì)人士包括

· 機(jī)構(gòu)投資者	· 生物技術(shù)公司
· 私募股權(quán)投資者	· 投資銀行
· 風(fēng)險(xiǎn)資本家	· 經(jīng)紀(jì)公司
· 天使投資人	· 證券交易所
· 家庭辦公室	· 顧問及分析師
· 基金經(jīng)理	· 律師事務(wù)所
· 主要制藥公司	· CMOS和CRO

大會(huì)日程

第一天 2013年10月28日		第二天 2013年10月29日
08:30	登記及茶點(diǎn)招待	08:30	登記及茶點(diǎn)招待
09:00	歡迎及正式開幕 The Honourable Gordon Rich-Phillips MLC, Minister for Technology, State Government of Victoria	09:00	歡迎及正式開幕 Dr Fintan Walton, Founder and CEO, PharmaVentures
09:10	會(huì)議主席致開場(chǎng)辭及交換名片 David Blake, Editor, Bioshares	09:15	生物技術(shù)融資和商業(yè)模式的發(fā)展 Kellee Kim, Research Analyst, ECOR1CAP
09:15	全球生物技術(shù)投資的趨勢(shì)和機(jī)會(huì) Dr Eric Shiozaki, Director, Apposite Capital	09:35	經(jīng)紀(jì)專題：生命科學(xué)個(gè)股票展望 Dr Fintan Walton, Founder and CEO, PharmaVentures Joanna Hill, Client Services Manager, EL & C Baillieu Stockbroking Steven Yatomi-Clarke, Director Corporate Finance, Patersons Securities Sam Street, Associate Director Corporate Finance, RBS Morgans James Posnett, Manager, Listing Business Development, ASX
09:35	探索不斷發(fā)展的生物技術(shù)投資環(huán)境——挑戰(zhàn)和機(jī)會(huì) David Blake, Editor, Bioshares Dr Jonathan Wang, Senior Managing Director, Orbimed Asia Jeremy Curnock Cook, Managing Director, Bioscience Managers Scott Power, Director of Research, RBS Morgans Dr Joshua Funder, Partner, GBS Venture Partners	09:35
10:15	生物技術(shù)公司聚焦介紹 Julie Phillips, CEO, BioDiem Dr John Holaday, Managing Director, CEO and CSO, QRxPharma Dr Brad Walsh, CEO, Minomic International Dr Greg Collier, CEO, Invion Howard Digby, Executive Director, EcoQuest	10:15	生物技術(shù)公司聚焦介紹 Geoffrey Kempler, Executive Chairman, Prana Biotechnology Dr Tom McCarthy, CEO & Managing Director, Spinifex Pharmaceuticals Roger McPherson, CFO, Patrys Dr Geoff Cumming, CEO, Anteo Diagnostics Dr Cliff Holloway, CEO, Immune System Therapeutics
11:00	早茶	11:00	早茶
11:30	改變中的生物技術(shù)投資環(huán)境 David Blake, Editor, Bioshares Lawrence Gozlan, Chief Investment Officer and Founder, Scientia Capital Michael Glenane, Executive Director, Fairview Equity Partners John Granger, Founder, Hawkesbury Partners Graeme Colley, Director of Technical and Professionals Standards, Self Managed Super Funds Professionals’ Association of Australia Ron Laufer, Senior Managing Director, Medimmune Ventures	11:30	澳大利亞維多利亞省州的生物技術(shù)產(chǎn)業(yè)能力 Representative, Victorian Government
		12:00	集資和投資而做知識(shí)產(chǎn)權(quán)盡職調(diào)查
		12:30	生物技術(shù)公司聚焦介紹 Simon Wilkinson, Director & CEO, Innate Immunotherapeutics Nick Weston, Chairman & CEO, Agenix Mike Thomas, CEO, iSonea Marc Storms, Marketing Manager, FEI
12:15	生物技術(shù)公司聚焦介紹 Dr Deborah Rathjen, CEO, Bionomics Dr Paul MacLeman, CEO, IDT Australia Dr Malcolm McColl, CEO, Viralytics Dr Michelle Miller, CEO, Biotron Charles Walker, CEO, Alchemia	13:05	午餐
12:15		14:15	亞洲區(qū)在生物技術(shù)創(chuàng)新和投資的角色越發(fā)壯大 Dr Jason Mann, Managing Director, Fenex Capital Management
13:00	午餐	14:35	如何引入中國(guó)投資？ Dr Fintan Walton, Founder and CEO, PharmaVentures Rob Scott, Director, China Bluesky Ventures Dr Benjamin Chen, Managing Partner, Ignatius Transaction Partners David Cheng, Chief Investment Officer, Coland Holdings Dr Jason Mann, Managing Director, Fenex Capital Management
14:00	衡量生物技術(shù)的機(jī)會(huì)，并優(yōu)化投資回報(bào)率 Dr Michael A. Berry, Managing Director, Discovery Investing
14:20	醫(yī)藥專題：組成戰(zhàn)略伙伴達(dá)至長(zhǎng)期的成功 David Blake, Editor, Bioshares Augustine Yee, Asia Pacific Head of Regional and Corporate Business Development and China Vice President of Business Development, AstraZeneca Dr James Garner, Vice President & General Manager, Takeda Global Research & Development Centre Asia, Takeda Dr Martin Judge, Director, Strategy and Sourcing, Novo Nordisk A/S Dr Brian Bloomquist, Senior Director, Global External Research and Development, Eli Lilly Dr Raman Rao, Head External R&D, Asia Pacific, Sanofi Pasteur
14:20		15:05	生物技術(shù)公司聚焦介紹 Uwe Schlokat, CEO, Sentinext Therapeutics Mark Heffernan, Chief Executive Officer, Nexvet Biopharma Nick Ede, Executive Director, Imugene Dr Clement Leong, Chief Executive Officer, Ascend Biopharmaceuticals
15:00	生物技術(shù)公司聚焦介紹 Carl Stubbing, Chief Business Officer, Benitec Biopharma Dr Julian Chick, COO, Allied Healthcare Group Dr Andrea Grant, CEO, Living Cell Technologies Mark Diamond, Managing Director & CEO, Antisense Therapeutics	15:40	下午茶
15:00		16:00	分拆創(chuàng)造價(jià)值 Dr Fintan Walton, Founder and CEO, PharmaVentures Dr Chris Nave, Chief Executive Officer, Medical Research Commercialisation Fund Dr John Kurek, Investment Manager, Uniseed Ventures Dr Mel Billingsley, President and CEO, The Life Sciences Greenhouse of Central Pennsylvania Ron Laufer, Senior Managing Director, Medimmune Ventures
15:35	下午茶
16:00	贏得在澳大利亞投資的稅后回報(bào)——策略和機(jī)會(huì) Helen Fisher, Corporate & International Tax Partner, Deloitte Sergio Duchini, R&D & Government Incentives Partner, Deloitte
16:00		16:30	生物技術(shù)公司聚焦介紹 Dr Richard Hopkins, CEO, Phylogica Paul Wright, CEO, Universal Biosensors
16:45	分析員圓桌會(huì)議：分析生物技術(shù)熱潮 David Blake, Editor, Bioshares Marc Sinatra, Equities Analyst, Lodge Partners Dr Graeme Wald, Investment Director, Bioscience Managers Scott Power, Director of Research, RBS Morgans Dr Matthijs Smith, Senior Analyst, Canaccord Genuity	16:50	生物技術(shù)在未來10年的挑戰(zhàn)和投資機(jī)會(huì) Dr Fintan Walton, Founder and CEO, PharmaVentures Glenn Cross, Chief Operating Officer, AusBiotech Todd Davis, Managing Director, Healthcare Royalty Partners Eric Shiozaki, Director, Apposite Capital Rhenu Bhuller, Global Vice President Pharmaceuticals/Biotechnology, Frost & Sullivan Dr Stewart Washer, Chairman, iSonea
17:30	第一天會(huì)議結(jié)束及招待酒會(huì)	17:30	主席致閉幕詞，會(huì)議結(jié)束